Search results
Results from the WOW.Com Content Network
The former head of Australian liver-cancer treatment firm Sirtex Medical Ltd has pleaded guilty to insider trading, Australia's corporate regulator said on Wednesday. Gilman Edwin Wong, who headed ...
Australian liver cancer treatment maker Sirtex Medical Ltd expects its $1.4 billion buyout by a Chinese consortium to will win regulatory approval in Australia and the United States despite ...
Sirtex targets metastatic colorectal cancer (mCRC) via SIR-Sphere microspheres. It has been thought that in 30-40% of individuals with severe illness, the liver is the only site of dissemination. At presentation, 20-25% of patients will have clinically identifiable liver metastases , and up to 50% of all patients develop liver metastases ...
Get breaking news and the latest headlines on business, entertainment, politics, world news, tech, sports, videos and much more from AOL
Sirtex Medical: Interim report - half-year ended 31 December 2012 Net profit after tax (NPAT) increased 27.6 per cent to $7.8 million Global dose sales growth of 30.5 per cent Total revenue ...
The acquisition of Sirtex will fortify Varian Medical's (VAR) footprint in Australia. The transaction is likely to close in late May 2018. ... News. 24/7 help. For premium support please call: 800 ...
For premium support please call: 800-290-4726 more ways to reach us
For premium support please call: 800-290-4726 more ways to reach us